vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and OPPENHEIMER HOLDINGS INC (OPY). Click either name above to swap in a different company.
Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($814.3M vs $472.6M, roughly 1.7× OPPENHEIMER HOLDINGS INC). OPPENHEIMER HOLDINGS INC runs the higher net margin — 15.7% vs 4.3%, a 11.4% gap on every dollar of revenue. On growth, OPPENHEIMER HOLDINGS INC posted the faster year-over-year revenue change (25.9% vs 11.5%). OPPENHEIMER HOLDINGS INC produced more free cash flow last quarter ($183.6M vs $108.5M). Over the past eight quarters, OPPENHEIMER HOLDINGS INC's revenue compounded faster (15.7% CAGR vs 11.1%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Oppenheimer Holdings Inc. is an American multinational independent investment bank and financial services company offering investment banking, financial advisory services, capital markets services, asset management, wealth management, and related products and services worldwide. The company, which once occupied the One World Financial Center building in Manhattan, now bases its operations at 85 Broad Street in New York City.
AMRX vs OPY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $814.3M | $472.6M |
| Net Profit | $35.1M | $74.4M |
| Gross Margin | 36.5% | — |
| Operating Margin | 13.8% | 22.4% |
| Net Margin | 4.3% | 15.7% |
| Revenue YoY | 11.5% | 25.9% |
| Net Profit YoY | 212.9% | 593.1% |
| EPS (diluted) | $0.10 | $6.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $814.3M | $472.6M | ||
| Q3 25 | $784.5M | $424.4M | ||
| Q2 25 | $724.5M | $373.2M | ||
| Q1 25 | $695.4M | $367.8M | ||
| Q4 24 | $730.5M | $375.4M | ||
| Q3 24 | $702.5M | $373.4M | ||
| Q2 24 | $701.8M | $330.6M | ||
| Q1 24 | $659.2M | $353.1M |
| Q4 25 | $35.1M | $74.4M | ||
| Q3 25 | $2.4M | $21.7M | ||
| Q2 25 | $22.4M | $21.7M | ||
| Q1 25 | $12.2M | $30.7M | ||
| Q4 24 | $-31.1M | $10.7M | ||
| Q3 24 | $-156.0K | $24.5M | ||
| Q2 24 | $6.0M | $10.3M | ||
| Q1 24 | $-91.6M | $26.1M |
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
| Q4 25 | 13.8% | 22.4% | ||
| Q3 25 | 9.0% | 7.5% | ||
| Q2 25 | 15.4% | 8.6% | ||
| Q1 25 | 14.4% | 11.2% | ||
| Q4 24 | 10.4% | 4.5% | ||
| Q3 24 | 12.6% | 9.5% | ||
| Q2 24 | 13.6% | 4.8% | ||
| Q1 24 | -1.6% | 10.6% |
| Q4 25 | 4.3% | 15.7% | ||
| Q3 25 | 0.3% | 5.1% | ||
| Q2 25 | 3.1% | 5.8% | ||
| Q1 25 | 1.8% | 8.3% | ||
| Q4 24 | -4.3% | 2.9% | ||
| Q3 24 | -0.0% | 6.6% | ||
| Q2 24 | 0.9% | 3.1% | ||
| Q1 24 | -13.9% | 7.4% |
| Q4 25 | $0.10 | $6.51 | ||
| Q3 25 | $0.01 | $1.90 | ||
| Q2 25 | $0.07 | $1.91 | ||
| Q1 25 | $0.04 | $2.72 | ||
| Q4 24 | $-0.10 | $0.92 | ||
| Q3 24 | $0.00 | $2.16 | ||
| Q2 24 | $0.02 | $0.92 | ||
| Q1 24 | $-0.30 | $2.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.0M | $38.4M |
| Total DebtLower is stronger | $2.6B | — |
| Stockholders' EquityBook value | $-70.8M | $983.8M |
| Total Assets | $3.7B | $3.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.0M | $38.4M | ||
| Q3 25 | $201.2M | $38.3M | ||
| Q2 25 | $71.5M | $37.6M | ||
| Q1 25 | $59.2M | $36.7M | ||
| Q4 24 | $110.6M | $33.1M | ||
| Q3 24 | $74.0M | $32.2M | ||
| Q2 24 | $43.8M | $33.2M | ||
| Q1 24 | $46.5M | $27.7M |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | $0 | ||
| Q3 24 | $2.4B | $112.8M | ||
| Q2 24 | $2.4B | $112.8M | ||
| Q1 24 | $2.4B | $112.7M |
| Q4 25 | $-70.8M | $983.8M | ||
| Q3 25 | $-109.5M | $920.3M | ||
| Q2 25 | $-112.1M | $896.9M | ||
| Q1 25 | $-131.7M | $872.3M | ||
| Q4 24 | $-109.3M | $850.4M | ||
| Q3 24 | $-93.4M | $837.8M | ||
| Q2 24 | $-57.5M | $812.1M | ||
| Q1 24 | $-63.7M | $801.5M |
| Q4 25 | $3.7B | $3.7B | ||
| Q3 25 | $3.6B | $3.8B | ||
| Q2 25 | $3.4B | $3.7B | ||
| Q1 25 | $3.4B | $3.6B | ||
| Q4 24 | $3.5B | $3.4B | ||
| Q3 24 | $3.5B | $3.4B | ||
| Q2 24 | $3.5B | $3.3B | ||
| Q1 24 | $3.5B | $3.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.3M | $188.8M |
| Free Cash FlowOCF − Capex | $108.5M | $183.6M |
| FCF MarginFCF / Revenue | 13.3% | 38.8% |
| Capex IntensityCapex / Revenue | 2.7% | 1.1% |
| Cash ConversionOCF / Net Profit | 3.72× | 2.54× |
| TTM Free Cash FlowTrailing 4 quarters | $269.9M | $191.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.3M | $188.8M | ||
| Q3 25 | $118.5M | $63.4M | ||
| Q2 25 | $83.8M | $40.1M | ||
| Q1 25 | $7.4M | $-91.7M | ||
| Q4 24 | $118.1M | $-108.2M | ||
| Q3 24 | $141.8M | $11.4M | ||
| Q2 24 | $39.7M | $-115.3M | ||
| Q1 24 | $-4.4M | $-79.0M |
| Q4 25 | $108.5M | $183.6M | ||
| Q3 25 | $106.2M | $62.2M | ||
| Q2 25 | $61.0M | $38.9M | ||
| Q1 25 | $-5.8M | $-93.4M | ||
| Q4 24 | $102.9M | $-113.3M | ||
| Q3 24 | $124.8M | $11.2M | ||
| Q2 24 | $29.0M | $-116.7M | ||
| Q1 24 | $-13.6M | $-79.3M |
| Q4 25 | 13.3% | 38.8% | ||
| Q3 25 | 13.5% | 14.7% | ||
| Q2 25 | 8.4% | 10.4% | ||
| Q1 25 | -0.8% | -25.4% | ||
| Q4 24 | 14.1% | -30.2% | ||
| Q3 24 | 17.8% | 3.0% | ||
| Q2 24 | 4.1% | -35.3% | ||
| Q1 24 | -2.1% | -22.5% |
| Q4 25 | 2.7% | 1.1% | ||
| Q3 25 | 1.6% | 0.3% | ||
| Q2 25 | 3.2% | 0.3% | ||
| Q1 25 | 1.9% | 0.5% | ||
| Q4 24 | 2.1% | 1.4% | ||
| Q3 24 | 2.4% | 0.1% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 1.4% | 0.1% |
| Q4 25 | 3.72× | 2.54× | ||
| Q3 25 | 50.00× | 2.92× | ||
| Q2 25 | 3.74× | 1.85× | ||
| Q1 25 | 0.61× | -2.99× | ||
| Q4 24 | — | -10.08× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | 6.62× | -11.23× | ||
| Q1 24 | — | -3.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
OPY
| Advisory Fees | $166.6M | 35% |
| Capital Markets Segment | $155.5M | 33% |
| Other | $57.2M | 12% |
| Commissions From Sales And Trading | $52.9M | 11% |
| Bank Deposit Sweep Income | $27.7M | 6% |
| Mutual Fund Income | $8.9M | 2% |
| Investment Banking Capital Markets | $3.3M | 1% |
